Aspire Pharma has announced Dr Andriy Krendyukov as its Chief Medical Officer, signalling a key step in company commitment to healthcare innovation.
He has held significant roles across different geographies in global and biotech companies such as Servier, Merz, Sandoz/Novartis and Apogenix.
Andriy has over 25 years in the healthcare system and pharmaceuticals environment, brings a wealth of expertise across therapeutic areas including oncology, neurology, cardiology, endocrinology and COVID-19.
In his role, Andriy will lead the Medical Office, driving Scientific and Regulatory Affairs, R&D, Clinical Operations, Safety and Pharmacovigilance, Quality and Compliance, ensuring Aspire Pharma remains at the forefront of medical advancement and patients access to care.
Meanwhile, Jonathan Chambers has recently joined Aspire Pharma as Senior Vice President – Scientific Affairs, to lead on the R&D, Compliance, Regulatory and Scientific Affairs functions.Jonathan brings with him a wealth of experience in clinical development, scientific affairs and new product development.
This includes clinical R&D leadership skills to deliver highly successful projects, across a variety of therapeutic areas, from specialty care to generic products. He joins Aspire after working as a Consultant Vice President (VP) at Mereo Biopharma.
His previous experience also includes working as European Medical Director at Otsuka Pharmaceuticals and Associate Director Operations, ACE Region, for Kite Pharma
